CABIO(SH:688089)2021-04-29 16:00Financial Performance - Operating revenue for the first quarter was ¥78,829,125.16, representing a growth of 41.47% year-on-year[5]. - Net profit attributable to shareholders of the listed company was ¥33,755,464.12, up by 33.12% compared to the same period last year[5]. - The net profit after deducting non-recurring gains and losses was ¥22,943,817.63, an increase of 25.82% year-on-year[5]. - Basic and diluted earnings per share were both ¥0.28, reflecting a growth of 33.33% compared to the previous year[5]. - The company reported a basic earnings per share of RMB 0.28, up 33.95% from RMB 0.21 in the same quarter last year[14]. - Net profit for Q1 2021 was ¥34,920,460.94, representing a 33.5% increase compared to ¥26,165,983.19 in Q1 2020[26]. - The company's net profit for Q1 2021 was CNY 30,888,845.13, an increase of 24.6% compared to CNY 24,869,740.10 in Q1 2020[30]. Revenue and Costs - The operating costs increased by 49.25% to RMB 36,909,551.39 from RMB 24,729,599.22, primarily due to the growth in operating revenue[14]. - Total operating costs for Q1 2021 were ¥50,963,252.55, up 56.9% from ¥32,499,184.56 in Q1 2020[25]. - Total revenue from sales of goods and services in Q1 2021 was CNY 69,446,652.09, an increase of 13.8% from CNY 60,973,599.77 in Q1 2020[31]. Research and Development - Research and development expenses accounted for 7.18% of operating revenue, an increase of 0.51 percentage points from the previous year[5]. - Research and development expenses rose by 52.25% to RMB 5,657,883.23, reflecting increased investment in new product development[14]. - Research and development expenses for Q1 2021 totaled ¥5,657,883.23, an increase of 52.4% from ¥3,716,081.05 in Q1 2020[25]. Cash Flow and Assets - The net cash flow from operating activities was -¥9,239,874.45, a decrease of 115.63% compared to the same period last year[5]. - The cash flow from operating activities showed a significant decline, with a net outflow of RMB -9,239,874.45 compared to a net inflow of RMB 59,120,168.55 in the previous year[14]. - The total monetary funds decreased by 66.65% to RMB 282,584,262.85 from RMB 847,316,269.30, mainly due to the purchase of bank wealth management products[13]. - The cash and cash equivalents at the end of Q1 2021 were CNY 279,404,885.04, down from CNY 374,213,008.21 at the end of Q1 2020[32]. - The company experienced a net cash outflow of CNY -565,433,555.68 in Q1 2021, compared to CNY -470,106,287.03 in Q1 2020[32]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,396,974,472.58, an increase of 1.02% compared to the end of the previous year[5]. - Current assets totaled RMB 1,131,760,224.96, slightly up from RMB 1,123,140,125.07, indicating a growth of about 0.2%[18]. - Total liabilities decreased to RMB 49,520,649.01 from RMB 59,301,062.31, a reduction of about 16.5%[19]. - Shareholders' equity increased to RMB 1,347,453,823.57 from RMB 1,323,519,628.48, reflecting a growth of approximately 1.8%[20]. - Non-current assets totaled RMB 265,214,247.62, up from RMB 259,680,565.72, indicating an increase of about 2.0%[18]. Shareholder Information - The total number of shareholders at the end of the reporting period was 5,200[10]. - The largest shareholder, Wuhan Xinyuan Bioengineering Co., Ltd., held 44.25% of the shares[11].